Literature DB >> 6872420

Elimination of amphotericin B in impaired renal function.

D J Morgan, M S Ching, K Raymond, R W Bury, M L Mashford, B Kong, J Sabto, F W Gurr, A A Somogyi.   

Abstract

The influence of impaired renal function on the steady-state plasma clearance of amphotericin B was determined in seven patients with creatinine clearances ranging from zero to normal. Contrary to previous reports, steady-state plasma concentrations of total drug were lower in uremic patients than in patients with normal renal function. Total plasma clearance of amphotericin B ranged from 16.7 to 39.9 ml/min, correlated directly with the plasma creatinine concentration, and correlated inversely with the creatinine clearance. Urinary excretion of unchanged drug accounted for less than 10% of the dose. In 10 healthy subjects, mean percent of amphotericin B unbound in plasma was 3.55 +/- 0.32 (SD). Binding was determined in a further group of 10 uremic patients. Mean unbound percent (4.15 +/- 0.73, SD) was higher than in the healthy subjects, and the binding ratio (molar concentration of bound to unbound drug) correlated weakly with the creatinine clearance. This suggests that plasma clearance of unbound amphotericin B and, therefore, steady-state plasma concentrations of unbound drug are not affected by renal impairment, and that dosage requirements will be overestimated if based on measurements of total drug plasma concentration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6872420     DOI: 10.1038/clpt.1983.161

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 3.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

4.  Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion.

Authors:  C E Nath; P J Shaw; R Gunning; A J McLachlan; J W Earl
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Sodium status influences chronic amphotericin B nephrotoxicity in rats.

Authors:  A Ohnishi; T Ohnishi; W Stevenhead; R D Robinson; A Glick; D M O'Day; R Sabra; E K Jackson; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

Review 6.  Amphotericin B nephrotoxicity.

Authors:  R Sabra; R A Branch
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

7.  Elucidation of human amphotericin B pharmacokinetics: identification of a new potential factor affecting interspecies pharmacokinetic scaling.

Authors:  G Robbie; W L Chiou
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

Review 8.  Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics.

Authors:  R Janknegt; S de Marie; I A Bakker-Woudenberg; D J Crommelin
Journal:  Clin Pharmacokinet       Date:  1992-10       Impact factor: 6.447

9.  Acute and chronic effects of flucytosine on amphotericin B nephrotoxicity in rats.

Authors:  H T Heidemann; K H Brune; R Sabra; R A Branch
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.